| Titre |
A Phase I and Enrichment Study of Low-dose Metronomic Topotecan and Pazopanib in Pediatric Patients With Recurrent or Refractory Solid Tumours Including CNS Tumours |
| Protocole ID |
IND.217 (TOPAZ) |
| ClinicalTrials.gov ID |
NCT02303028 |
| Type(s) de cancer |
Pédiatrique divers |
| Phase |
Phase I |
| Institution |
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dre Monia Marzouki
|
| Coordonnateur(trice) |
Linda Hershon
514-345-4931 poste 5899
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
-
Disease: Part 1-Relapsed or refractory solid tumours including CNS tumours; Part 2A-Neuroblastoma, Part 2B Rhabdomyosarcoma
-
Measurable or evaluable disease
-
No known curative therapy, or therapy proven to prolong survival with an acceptable QOL
-
Organ Function Criteria
-
Peripheral ANC ≥ 1,500/μL; Plt ≥ 100,000/ and Hb ≥ 80 g/L (RBC transfusion permitted)
-
Measured creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2, OR a serum creatinine based on age/gender that meets the criteria outlined in the protocol
-
Urinalysis negative for protein, urine protein:creatinine ratio of ≤ 1, OR a 24-hour urine protein < 1000 mg/dL
-
<Gr.1 abnormalities of K, Ca (confirmed by ionized Ca),Mg or Ph (supplementation allowed)
-
Total serum bilirubin ≤ 1.5xULN for age
-
SGPT (ALT) ≤ 2.5 x ULN and SGOT (AST) ≤ 2.5 x ULN
-
Serum albumin ≥ 20 g/L
-
Adequate systolic ventricular function (LVSF≥ 27% or LVEF ≥ 50%)
-
QTc measured by ECG must be < 450 msec.
-
No history of MI, severe or unstable angina, peripheral vascular disease, or familial QTc prolongation
-
Blood pressure ≤ 95th percentile for age, height, gender AND one of:
-
No current anti-hypertensive therapy, OR on stable doses of no more than one anti-hypertensive medication
-
Subjects with known history of seizures must have well-controlled seizures and not receiving enzyme-inducing anti-convulsants
-
INR ≤ 1.2 and PTT ≤ 1.2xULN
-
Prior Therapy
-
Myelosuppressive chemo must not have been given within 3 weeks of study enrolment (6 weeks if nitrosourea)
-
At least 7 days must have elapsed since completion of therapy with a growth factor that supports platelet or white cell number or function. At least 14 days must have elapsed after receiving pegfilgrastim.
-
Biologic anti-neoplastic agent (including VEGF-blocking TKI) must not have been administered within 7 days of study enrolment
-
At least 3 half lives of the monoclonal antibody must have elapsed since the last dose administered
-
≥ 2 weeks must have elapsed since local palliative XRT (small port); > 13 weeks since prior total body irradiation (TBI), craniospinal XRT or > 50% radiation of pelvis; or > 6 weeks if other substantial bone marrow irradiation
-
≥ 8 weeks must have elapsed since MIBG therapy for neuroblastoma
-
At least 60 days must have elapsed from autologous or allogeneic stem cell transplant with no signs of GVHD.
-
At least 28 days from major surgery and wounds must be healed. At least 7 days from open and/or core biopsy.
-
Ability to take liquid medication by mouth
|
| Critètes d'exclusion |
-
Patients with DIPG, or known CNS metastases
-
Pregnancy, breast feeding, or unwillingness to use effective contraception during the study
-
Subjects currently receiving:
-
Corticosteroids who haven't been on a stable or decreasing dose of corticosteroid for 7 days prior
-
Another investigational drug; other anti-cancer agents or radiation therapy
-
More than one medication for blood pressure control
-
Therapeutic anticoagulation, including systemic use of warfarin, heparin, or low molecular weight heparin at any dose
-
Aspirin, and/or ibuprofen, or other NSAIDs
-
Drugs metabolized through several of the specific P450 cytochrome isoforms and those receiving drugs with a known risk of torsades de pointes
-
Subjects who require thyroid replacement therapy are not eligible if they have not been receiving a stable replacement dose for at least 4 weeks prior to study enrolment.
-
Subjects who have an uncontrolled infection or serious non-healing would, ulcer or bone fracture.
-
Evidence of active bleeding, intratumoral haemorrhage, or bleeding diathesis, hemoptysis or any evidence of GI hemorrhage.
-
Major surgical procedure, laparoscopic procedure or significant traumatic injury within 28 days prior to Day 1 therapy. Open or core biopsy within 7 days prior to Day 1 of therapy.
-
Previous, documented hypersensitivity reactions to topotecan or pazopanib
-
History of abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days of study enrolment.
|
Groupe d'étude en oncologie du Québec